SCM
GNCA

Segantii Capital Management’s Genocea Biosciences, Inc. GNCA Stock Holding History

Segantii Capital Management’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3,287
Closed -$160K – 355
2017
Q1 		$160K Buy
+3,287
New +$128K 0.03% 167

Other funds holding GNCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Segantii Capital Management's GNCA Position: Q2 2017 in Review

Segantii Capital Management sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2017, closing a stake of 3,287 shares — an estimated $160K sold.

Segantii Capital Management first reported a position in GNCA in Q1 2017 and held it in 1 quarter. The position peaked at $160K in Q1 2017. 61 funds tracked by Wall St. Rank hold GNCA as of Q2 2017.

  • Segantii Capital Management reported no remaining Genocea Biosciences, Inc. position as of Q2 2017 after selling out during the quarter.
  • Segantii Capital Management sold 3,287 Genocea Biosciences, Inc. shares in Q2 2017, an estimated $160K.
  • Segantii Capital Management first reported a position in Genocea Biosciences, Inc. in Q1 2017 and held it in 1 quarter.
  • Segantii Capital Management's Genocea Biosciences, Inc. position peaked at $160K in Q1 2017.
  • 61 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2017.

Based on Segantii Capital Management's 13F filing for Q2 2017, filed 2 Aug 2017.